Show an ad over header. AMP

I am the FIRST!!!

Retail sales' mixed bag and what it means for the economic recovery

Retail sales fell by a lot more than experts expected in July. However, the shopping trends underlying the data don’t paint a picture of nervous consumers pulling back amid renewed COVID concerns.

Why it matters: The recent spike in COVID cases amid the spread of the Delta variant has taken a toll on consumer sentiment. Should that drop in sentiment translate into a significant downturn in actual spending, the U.S. economic recovery could be thrown off track.


By the numbers: Retail sales in July declined by 1.1% from June levels, according to a Tuesday Census report. That was much worse than the 0.3% decline expected.

  • Leading the decline was a 3.9% drop in motor vehicle and parts dealers sales. The auto industry, however, is working through well-known supply chain issues.
  • Yet excluding autos, retail sales still unexpectedly fell by 0.4%, which was also worse than the 0.2% gain expected by economists.

Between the lines: Online retailer sales fell by 3.1% during the month. The category accounts for about 14% of total retail sales.

  • Multiple economists Axios follows, however, noted this reflected Amazon’s Prime Day, which occurred in June. The event, which even had Amazon’s online competitors offering aggressive deals, had the effect of pulling demand forward, depressing sales in the subsequent month.
  • "The miss was largely in online retailing," Renaissance Macro economist Neil Dutta said of July’s retail sales report.

Zoom out: If there’s one bigger picture theme that explains the report, it’s that consumers are spending more on services and less on goods, reversing behavior adopted during the lockdowns.

  • "The largest declines were in Covid-advantaged categories," Morgan Stanley chief U.S. economist Ellen Zentner said, pointing to sporting goods, books, building materials and furniture.
  • Spending at restaurants and bars jumped 1.7%, which conflicts with the idea that the Delta variant wave has caused consumers to spend less.

Yes, but: "Data on mobility is starting to show a pull back, especially in hot spots in the South," GrantThornton chief economist Diane Swonk said.

The bottom line: July economic data doesn’t conclusively signal that the spike in COVID cases is leading to a retrenchment in spending. However, it also doesn’t suggest the economy is in the clear.

  • "Fear acts as its own deterrent on congregating," Swonk said. "Spread of the Delta variant and vaccine hesitancy have begun to collide. We are in for a rockier second half of the year."

regular 4 post ff

infinite scroll 4 pff

"No more lies": What drove Cubans to protest

Data: Proyecto Inventario; Map: Will Chase/Axios

Sara Naranjo, 88, took to Cuba's streets this past week because she is "done with being hungry, unemployed, without water, without power." Naranjo is one of thousands of Cubans to take part in what activists said were the largest anti-government protests on the island in decades.

What's happening: People like Naranjo, who remembers Cuba before the revolution, joined thousands of younger Cubans, who have only known Communism, in the massive street protests despite their fear of the government’s harsh response.

Keep reading... Show less

Latin America and the Caribbean wait for COVID-19 vaccines

Data: Our World In Data; Map: Axios Visuals

Latin America and the Caribbeanhave the highest weekly death rate per capita of any region in the world, and it could climb, with vaccinations difficult to come by and hospitals still short on staff and equipment like ventilators and oxygen tanks.

Why it matters: Fewer than 10% of the people of Latin America and the Caribbean have been fully vaccinated against COVID-19 since immunization campaigns started in December, mostly due to the low availability of doses.

Keep reading... Show less

The drug pricing lawsuit that could blow up Medicare

A federal judge will soon determine whether Pfizer can pay Medicare patients' out-of-pocket expenses for one of its heart medications that is priced at $225,000 per year.

Why it matters: A ruling in Pfizer's favor would legalize something that is viewed as a kickback under current law, and would jeopardize taxpayer coffers by spurring a "gold rush" of pharmaceutical companies to cover Medicare copays for expensive drugs.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories
]> &lol4;